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Antimycobacterial activity of acetone and water extracts
of Helichrysum caespititium against a drug-sensitive
strain of Mycobacterium tuberculosis was evaluated by
the agar plate method. The acetone extract exhibited
inhibitory activity at a concentration of 0.5mg ml-1
against this strain whereas the organism was found to be
partially susceptible to the water extract at 5.0mg ml-1.
The inhibitory activity of the acetone extract was con-
firmed using the rapid radiometric method and the min-
imum inhibitory concentration (MIC) was found to be
0.1mg ml-1. Caespitate, a novel phloroglucinol, which
was previously isolated and identified, from H. caespiti-
tium was also evaluated for its activity against drug-
sensitive and drug-resistant strains of M. tuberculosis.
The MIC of caespitate was found to be 0.1mg/ml for all
the M. tuberculosis strains. The ability of caespitate to
inhibit the growth of all the strains of M. tuberculosis,
shows the broad spectrum antimycobacterial activity of
the compound.
The resurgence of tuberculosis (TB) in recent years in many
regions of the world, especially in developing nations has
made the search for novel strategies to combat this infec-
tious disease indispensable. TB is the leading cause of
death worldwide claiming more adult lives than diseases
such as AIDS, malaria, diarrhoea, leprosy and all other trop-
ical diseases combined (Zumla and Grange 1998). About
one third of the world’s population is currently infected with
Mycobacterium tuberculosis, while 10% of those infected will
develop the clinical disease, particularly those with human
immunodeficiency virus (HIV) infection (Wilkinson et al.
1996). According to World Health Organisation it is estimat-
ed that between 2000 and 2020, nearly 1 billion more peo-
ple will be newly infected, 200 million people will get sick and
70 million will die from TB if the control of the disease is not
strengthened (New Scientist 1998).
The organism usually responsible for TB is the tubercle
bacillus, Mycobacterium tuberculosis, discovered by Robert
Koch in 1882. TB is usually acquired by inhalation of the
bacillus from an infectious patient and causes irreversible
lung destruction. Today, many bactericidal and bacteriostat-
ic drugs are used in combination all over the world with dra-
matic positive results and tuberculosis has become a cur-
able disease. Even with the advent of such powerful specif-
ic antimicrobials, a long duration of treatment with either
daily or intermittent therapy is required. In the presently
available treatment regimes of 6–9 months duration, the
patients frequently stop taking drugs as soon as the symp-
toms are ameliorated and the treatment is therefore discon-
tinued. This leads to the emergence of multidrug resistant
TB, a problem for which more toxic second-line drugs, have
to be used. According to a WHO report, globally, 2% of all
cases of tuberculosis are multidrug resistant — by definition,
resistance to rifampicin plus isoniazid (plus other resistanc-
es). Such cases can be treated in the USA and other high -
resource regions but at a great cost (>US$250 000 per
case!) and using very long courses of rather toxic drugs,
thereby raising serious problems of compliance (WHO
1997). South Africa is witnessing an explosion in the number
of cases of drug-resistant tuberculosis. An estimated 2 000
South Africans contract multidrug resistant TB each year
and more than half of these patients die within a period of
two years (WHO/TB/98.258 1998). It is essential to have
new antituberculosis agents, preferably those that can read-
ily and simply be produced from some local source.
Plants have been used worldwide in traditional medicines
for the treatment of various diseases. It is estimated that
even today, approximately two-thirds to three-quarters of the
world’s population rely on medicinal plants as their primary
source of medicines (Phillipson and Anderson 1989). The
use of some medicinal plants such as Vernonia woodii,
Conyza ivaefolia, a number of Helichrysum species such as
Helichrysum caespititium, H. leiopodium, H. appendiculatum,
etc., by South Africans in curing TB-related symptoms such
as cough, fever, blood in the sputum has been reported. The
leaves of H. imbricatum and H. nudifolium are being used as
a tea and an infusion as a demulcent in coughs and in pul-
monary affections. It has been reported that people smoke
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the dried flower and seed of H. krausii in a pipe for the relief
of cough and as a remedy for pulmonary tuberculosis (Watt
and Breyer-Brandwijk 1962). However, only a small propor-
tion of plant species have been thoroughly investigated for
their medicinal properties and undoubtedly there are many
novel biologically active compounds to be discovered.
Helichrysum caespititium (DC.) Harv. (Asteraceae) is a
prostrate, perennial, mat-forming herb that is profusely
branched and densely tufted. It has been reported that the
Basotho, a South African tribe, and indigenous people of
Zimbabwe inhale smoke from the burning plant for the relief
of headache, colds and chest pain. Exudates of this herb are
claimed to be effective against broncho-pneumonial dis-
eases, sexually transmitted diseases, tuberculosis and
ulceration (Watt and Breyer-Brandwijk 1962, Gelfand et al.
1985). However, not much attention has been given to the
laboratory evaluation and detection of antituberculosis activ-
ity of H. caespetitium. We, therefore, decided to investigate
the antimycobacterial effect of plant extracts and a phloglu-
cinol isolated from it against drug-sensitive and drug-resist-
ant strains of M. tuberculosis. We also compared our results
of susceptibility testing by the agar plate method with that of
the radiometric method.
Materials and Methods
Plant material
Shoots of H. caespititium were collected near Harrismith and
identified at the HGWJ Schweickerdt herbarium of the
University of Pretoria and also at the herbarium of the
National Botanical Institute, Pretoria. A voucher specimen
(AM11) of the species was deposited in the herbarium of the
National Botanical Institute of South Africa, in Pretoria.
Preparation of plant extracts
Dried aerial plant parts of H. caespititium (40g) were
immersed in acetone and shaken on a rotary shaker for 5 min-
utes. The extract was filtered and evaporated to dryness in
vacuo at 40°C. The acetone residue was dissolved in dimethyl
sulphoxide (DMSO) to obtain a final concentration of 500mg
ml-1 because of the toxicity of acetone towards bacteria.
The water extract was prepared by boiling ca. 20g of plant
material in 500ml of distilled water for 30min under reflux.
The extract was filtered and concentrated to dryness at
reduced pressure. The residue was dissolved in distilled
water to give a final  concentration of 500mg ml-1.
Isolation of a phloroglucinol
A novel phloroglucinol, caespitate (2-methyl-4-[2’,4’,6’-trihy-
droxy-3’-(2-methylpropanoyl) phenyl]but-2-enyl acetate) [1]
was isolated from the crude acetone extract of H. caespiti-
tium (Figure 1) as described earlier by Mathekga et al.
(2000). The crude acetone extract was initially subjected to
preparative thin layer chromatography in CHCl3-EtOAc (1:1).
The targeted band was recovered and rechromatographed
by column chromatography with 100% chloroform on silica
gel 60. The compound was finally purified by high perform-
ance liquid chromatography in H2O-Et OH (1:1) on a reverse
phase Phenomenex column (250 x 4.60mm, 5m).
Determination of antimycobacterial activity
Preparation of bacterial media
One litre of Middlebrook 7H11 agar (Difco Laboratories) con-
taining 0.5% glycerol was prepared for susceptibility testing
by the agar plate method (Middlebrook and Cohn 1958). The
acetone and water plant extracts (500mg ml-1) were ster-
ilised by filtration through 0.22mm syringe fitted filters and
then incorporated in the medium before solidification, to
obtain final concentrations of 5.0, 1.0 and 0.5mg ml-1.
Control experiments showed that the final amount of DMSO
(1%) in the media had no effect on the growth of M. tuber-
culosis. The mixture (10ml) of plant extract and medium was
poured in glass bottles and solidified in slants. All tests were
done in triplicate.
Preparation of  inocula and interpretation of results
Bacterial cultures utilised in this study were grown from
specimens received from the Medical Research Council
(MRC) in Pretoria. These cultures were routinely tested for
susceptibility to the primary drugs streptomycin (SM), isoni-
azid (INH), ethambutol (EB) and rifampicin (RIF). A drug-
sensitive strain of M. tuberculosis, H37Rv reference strain,
was also used in the screening procedure.
Standard inoculum was prepared for the sensitive strain in
Middlebrook-Dubos 7H9 broth containing 0.5% Tween 80 to
obtain a concentration of 1mg ml-1 (wet mass) as described
previously by Lall and Meyer (1999). The H37Rv sensitive
strain suspension was divided into two portions. One portion
was saved for the rapid radiometric susceptibility test and
the other was used for the agar plate susceptibility testing.
The suspension was diluted to 1x10-2mg ml-1 and 1x10-4
mg ml-1. To each bottle containing plant extract, 0.2 ml of the
1x10-2mg ml-1 of bacterial suspension was added. For the
control tubes (medium + 1% DMSO), 0.2ml of the two dilu-
tions (1x10-2 and 1x10-4mg ml-1) of the inoculum were used.
The antimicrobial activity was evaluated after 6 weeks of
incubation at 37°C. The number of colonies growing on the
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Figure 1: Caespitate (2-methyl-4-[2’,4’,6’-trihydroxy-3’-(2-methyl-
propanoyl) phenyl]but-2-enyl acetate) isolated from Helichrysum
caespititium
Meyer, Lall and Mathekga92
medium with plant extracts, containing the dilution 1x10-2mg
ml-1 of the inoculum (N-2) was compared with the growth on
the control series, containing dilutions 1x10-2mg ml-1 (NO-2)
and 1x10-4mg ml-1 ( NO-4) of the inoculum.
The following criteria were used for the interpretation of
the results:
N-2 ≥ NO-2 : the strain is considered as resistant;
NO-4 ≤ N-2 ≤ NO-2 : the strain is considered as partially sus-
ceptible;
N-2 ≤ NO-4 : the strain is considered as sensitive
(<1% growth).
All procedures involving transfer of cultures were carried out
in a biological safety cabinet.
The radiometric method
The activity of acetone plant extract was found to be 0.5mg
ml-1 against the H37Rv strain by the agar plate method. It
was decided to compare this result with the radiometric
method. Acetone extract of the plant was analysed for activ-
ity at concentrations of 1.0, 0.5 and 0.1mg ml-1 against a
sensitive strain. A novel phloroglucinol, caespitate (2-methyl-
4-[2’,4’,6’-trihydroxy-3’-(2-methylpropanoyl) phenyl]but-2-
enyl acetate) [1] isolated from the plant was also evaluated
against drug-sensitive and 2–7 drug resistant strains at con-
centrations of 0.1, 0.05 and 0.01mg ml-1 (Table 1). All tests
were done in triplicate.
The crude acetone extract and the compound [1] were
each dissolved at 10mg ml-1 in 1% DMSO and stored at -4°C
until used. Subsequent dilutions were done in DMSO and
added to 4ml of BACTEC 12B broth (7H12 medium) to
achieve the desired final concentrations together with
PANTA (Becton Dickinson and Company), an antimicrobial
supplement. BACTEC drug susceptibility testing was also
done for the two primary TB-drugs, streptomycin and etham-
butol at concentrations of 6mg ml-1 and 7.5mg ml-1 respec-
tively, against the H37Rv strain.
A homogenised culture (0.1ml) of all the strains of M.
tuberculosis, yielding 1x104 to 1x105 colony forming units ml-1
(CFU ml-1), were inoculated in the vials containing the plant
extract, compound as well as in the control vials (Heifets et
al. 1985). Two plant extract-free vials were used as controls:
one vial was inoculated in the same way as the vials con-
taining the compound [1], and the other was inoculated with
a 1:100 dilution of the inoculum (1:100 control) to produce
an initial concentration representing 1% of the bacterial pop-
ulation (1x102 to 1x103 CFU ml-1) found in the vials contain-
ing crude extract and the compound. The minimum inhibito-
ry concentration (MIC) was defined as the lowest concen-
tration of the compound that inhibited more than 99% of the
bacterial population.
When mycobacteria grow in 7H12 medium containing 14C-
labeled substrate, they utilise the substrate and 14CO2 is pro-
duced. The amount of 14C02 detected reflects the rate and
amount of growth occurring in the vial, and is expressed in
terms of the Growth Index (GI). Inoculated bottles were incu-
bated at 38°C and each bottle was assayed every day to
detect GI, at about the same hour until cumulative results
were interpretable. The difference in the GI values of the last
two days is designated as DGI. The GI reading of the vials
containing the plant extract was compared with the control
vial, containing a 1:100 dilution of the inoculum. Readings
were taken until the control vials containing a 100 times lower
dilution of the inoculum, than the vials with plant extract,
reached a GI value of 30 or more. If the DGI value of the vial
containing the plant extract was less than the control, the
population was recorded to be susceptible to the extract.
Results and Discussion
The plate method
Good growth of M. tuberculosis (H37Rv) was evident in the
bottles containing only Middlebrook medium, within 5 to 6
weeks. All the results were reported after 6 weeks. The MIC
of acetone extract was found to be 0.5mg ml-1 for a drug-
sensitive strain of M. tuberculosis. The acetone extract
inhibited growth of the organisms at concentrations ranging
from 0.5 to 5.0mg ml-1. The organism was found to be par-
tially susceptible to the water extract at the highest concen-
tration 5.0mg ml-1 tested.
The radiometric method
Results were interpreted on day 6 or 7 when the control vials
containing the 1:100 dilution of the inoculum reached a GI
value of 30 or more (Table 1). The DGI values of the vials
containing streptomycin and ethambutol was found to be 4 ±
Table 1: Effect of crude acetone extract of H. caespititium and caespitate isolated from it on the growth of the drug-sensitive strain (H37Rv)
and drug-resistant strains of Mycobacterium tuberculosis by the radiometric method
M. tuberculosis strains and degree of resistance Lab ref. no. of strains MIC (mg ml-1) ΔGIb values ΔDGI values of
to antibiotic drugsa the control vialsb
Drug-sensitive strain (H37Rv) (crude extract) ATCC27294 0.1 5.33 ± 2.12     25 ± 4
Drug-sensitive strain (H37Rv) (caespitate) ATCC27294 0.1 7.33 ± 4.93     25 ± 4
Resistant to I and R CCK028469V 0.1 7 ± 2      26 ± 3.2
Resistant to S, I and E1 C9 0.1 3 ± 1.73    17.33 ± 3.05
Resistant to S, I, R and E1 C84 0.1 8.66 ± 1.52      23 ± 3.5
Resistant to I, S, R, T1 and C CGT1296429 0.1 8.3 ±  2.88    23.3 ± 3.51
Resistant to I, R, E2, T1, T2 and O CCK070370H 0.1 10 ±  3.60      27 ± 5.56
Resistant to I, S, E1, E2, K, R, and T1 CGT1330497 0.1 10.3 ± 2.52      26.33 ±  7.09
aI, isoniazid; R, rifampin; S, streptomycin; E1, ethambutol; E2, ethionamide; T1, thiacetazone; T2, terizidone; C, cyclocerine; O, ofloxacin; K,
kanamycin. bΔGI values are means ± s.d.
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1.41 and 6 ± 3.12 respectively. Crude acetone extract of H.
caespititium showed inhibitory activity against the sensitive
organism at a concentration of 0.1mg ml-1. Among other
Helichrysum species investigated earlier for their anti-TB
activity, it was found that MICs of crude acetone extracts of
H. melanacme and H. odoratissimum against the sensitive
strain of M. tuberculosis were 0.1 and 0.5mg ml-1respective-
ly (Lall and Meyer 1999). A previous evaluation of the antimi-
crobial activity of the crude acetone extract of H. caespiti-
tium showed inhibitory activity against fungi, Gram-positive
as well as Gram-negative bacterial species at concentrations
ranging from 0.01–1.0mg ml-1 (Mathekga and Meyer 2001).
Chemical investigations of Helichrysum species have
revealed that they are rich sources of acetophenones,
flavonoids, sesquiterpenoids and phloroglucinols which are
probably used in chemical defence mechanisms of plants
against bacteria and fungi (Hilliard 1983). In the present
study, the MIC of the phloroglucinol, caespitate, isolated from
the plant was found to be 0.1mg ml-1 for all the M. tuberculo-
sis strains. An earlier antimicrobial investigation of this com-
pound showed it to be highly active against bacteria and fungi,
exhibiting an MIC ranging from 0.5μg ml-1 to 1.0μg ml-1
(Mathekga et al. 2000). In another study, caespitin, a
phloroglucinol structurally similar to caespitate, also isolated
from H. caespititium, demonstrated significant antibacterial
properties (Dekker et al. 1983).
It is generally agreed that at least one acidic hydroxyl group
and a certain degree of lipophilicity are required for biological
activity of compounds (Tomas-Barberan et al. 1990). In the
present study, the anti-TB compound isolated from H. caespi-
titium bears 3 hydroxyls (phenolic hydroxyls) and lipophilicity
(3’-isobutyrylphenyl and but-2-enyl acetate residues).
However, it requires further verification by testing structurally
related phloroglucinols to determine the essential active
regions necessary for significant antituberculosis activity.
The results obtained from the radiometric method were
satisfactory and comparable with that obtained from the
plate method. The time period required by the radiometric
method for susceptibility testing was only 6 to 7 days as
compared to 6 weeks by the plate method. Results can
therefore be obtained significantly faster than with the plate
method because in liquid medium there is more cells to drug
contact and due to the shorter incubation time, also less like-
lihood of breakdown of the tested compounds.
This study provides a probable scientific explanation for
the therapeutic potency attributed to H. caespititium, claimed
by traditional healers in the Free State province of South
Africa. The traditional use of H. caespititium extract against
sores, colds, and tuberculosis could possibly be attributed to
the activity of caespitate. The crude acetone extract and the
isolated compound, caespitate did not show activity at the
level of the two positive controls tested. Although this makes
it unlikely that the compound and crude extract themselves
are candidates for further development, they could act as
templates for analogues and it would be interesting to deter-
mine if any synergistic effects might occur if the active com-
pound and established anti-tubercular compounds were
administered together. Secondly, it is possible that there
could be other antimycobacterial compounds present in the
plant as the MIC of the crude extract was similar to the MIC
of the isolated compound. Research is underway to isolate
and identify other compounds with antimycobacterial activi-
ty from the shoots of H. caespititium.
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